clinical trial · NCT07158710
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Haisco Pharmaceutical Group Co., Ltd.·phase1·recruiting·n = 159
Malignant Brain TumorsHSK42360
brief summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.
started
Aug 15, 2025
primary completion
May 23, 2029
completion
Dec 3, 2029
last updated
Sep 8, 2025
official title
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HSK42360 in Pediatric Patients With BRAF V600-Mutant Malignant Brain Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol